On treatment outcome prediction and adjustment during chronic hepatitis B therapy: Now and future

Antiviral Therapy

Volumn 14, Issue 1, 2009, Pages 13-22

  Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LONG TERM CARE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENINE; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; MEDICATION ADHERENCE; NUCLEOSIDES; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS; PROGNOSIS; PYRIMIDINONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 61849132825     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther 2008; 13 Suppl 1:3-8.
2. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl 1:9-16.
3. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22:615-633.
4. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
5. Hadziyarmis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-907.
6. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
7. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
8. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
9. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
10. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
11. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
12. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283,
13. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006; 4:666-676.
14. Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008; 2:102
15. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38:1267-1273.
16. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117.
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751.
18. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
19. Heathcote EJ, Gane EJ, Marcellin P, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103). Hepatology 2008; 48 Suppl 1:376A.
20. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2 Suppl 2: S76.
21. van Bömmel F, Wimsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421-1425.
22. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
23. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Gastroenterology 2009; 45:486-495.
24. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivuciine-refractory chronic hepatitis B: unProved viroloesic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48:99-108.
25. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30:77d-774.
26. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699-705.
27. Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW. Interferon-α therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000; 7:382-386.
28. Fried MW, Piratvisuth T, Lau GKK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with pegintcrferon alfa-2a for HBeA pos t chronic hepatitis B. Hepatology 2008; 47:428-4341.
29. ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44:721-727.
30. Farci P, Marcellin P, Lu ZM, et al. On-treatment predictors of sustained biochemical and vriological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon θa-2a (40kD) (Pegasys(®). J Hepatol 2005; 42 Suppl. 2:175.
31. Chan HL, Wong VW, Chim AM, Wong GL, Chan HY, Sung JJ. Treatment of patients with chronic hepatitis B who e ed previous antiviral treatment with pegylated interferon-α2a (40 kDa; [bPEGASYS®). Antivir Ther 2008; 13:555-562.
32. Chan HL, Wong VW, Wong GL, Chim AM, Chan HY, Sung JJ. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008; 6:1022-1026.
33. Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13:57-66.
34. Lau GKK, Marcellin P, Brunetto M, et al. On-treatment HBsAg decline during peginterferon alfa-2a (40KD) ±lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response. Hepatology 2008; 48 Suppl 1:714A.
35. Marcellin P, Brunetto M, Bonino F, et al. In patients with HBsA negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Hepatology 2008; 48 Suppl 1:718A.
36. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180: 1757-1762.
37. Zöner B, Schf̈er P, Feucht HH, Schrẗer M, Petersen J, Laufs R, Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001; 65: 659-663.
38. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivadine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536.
39. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147:745-754.
40. Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12:345-353.
41. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46:1695-1703.
42. Hadziyannis AS, Mitsoula PV, Hadziyannis SJ. Prediction of long-term maintenance of virologic response during larnivuidne treatment in HBeA9 negative chronic hepatitis B. Hepatology 2007; 46 Suppl 1:667A.
43. Gallego A, Sheldon J, Garcia-Samaniego J, et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008; 15:392-398.
44. Pritchett S, Wong DK, Yim C, Mazzulli T, Heathcote EJ. Factors adecting response to adefovir treatment in patients with chronic hepatitis B and lamivudine resistance. Hepatology 2007; 46 Suppl 1:675A.
45. Park NH, Shin JW, Park JW, et al. Predictors of virologic response and resistance to adefovir in patients with lamivudine-resistance chronic hepatitis B virus infection. Hepatology 2007; 46 Suppl 1:675A.
46. Han WS, Yeon JE, Kim YH, et al. Virologic response at treatment month 12 may predict sustained antiviral efficacy in adefovir treated lamivudine-resistant chronic hepatitis B. J Hepatol 2007; 46 Suppl 1:S188.
47. Entecavir (BMS-200475) Antiviral Drugs Advisory Committee. (AVDAC) briefing document. (Accessed 15 August 2008.) Available from http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2O05-4094B_101_BristolMyersSquibb-entecavir.pdf
48. Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fulmarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data. J Hepatol 2008; 48 Suppl 2:S32.
49. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged larnivudine therapy. Hepatology 2001; 34:785-791.
50. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42 Suppl 2:17.
51. Castel H, Osiowy C, Heathcote EJ, Willems B, Villeneuve JP. Is viral load at week 48 predictive of adefovir resistance in HBV patients receiving adefovir for lamivudine resistance? J Hepatol 2008; 48 Suppl 2:S255.
52. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
53. Lau G, Marcellin P, Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007; 1:316-325.
54. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437-1444.
55. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008; 13:211-220.
56. Hwang SG, Gane E, Safadi R, et al. Telbivudine versus lamivudine in lamivudine experienced patients: primary analysis at week 24. Hepatol Int 2007; 1:14.
57. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok ASF. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48:391-398.
58. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5:890-897.